Startup profile · funding coverage
CoFlo Medical funding, valuation and investors
Develops injection devices for high-viscosity medicines.
Verified company research · funding, investors and latest developments
Keep track of CoFlo Medical
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed announced; instrument composition undisclosed
USD 6 million; instrument composition undisclosed · November 19, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · San Francisco, California, United States
Investors in latest funding
Lead: J2 Ventures
Overview
CoFlo Medical develops drug-delivery devices based on core annular flow. Its cofounders are Simon Rufer, CEO; Vishnu Jayaprakash, chief business officer; and MIT professor Kripa Varanasi, chairman. The company describes its platform as a way to move concentrated medicines through needles with less resistance.
Why CoFlo Medical is interesting
Viscosity can limit how a concentrated medicine is delivered. CoFlo addresses that engineering constraint, but a useful drug/device combination still requires formulation compatibility and product-specific validation. Laboratory demonstrations and financing do not establish clinical outcomes or regulatory clearance.
Product & use cases
A lower-viscosity sheath surrounds the medicine as both fluids pass through the needle. The company says the sheath must be compatible with the drug and is injected along with it. Its website lists Gen One, Double Barrel and CO-AXL hub configurations for development with pharmaceutical partners.
- Developing delivery configurations for concentrated, viscous drug formulations.
- Evaluating compatible sheath fluids and injector configurations with pharmaceutical developers.
Key facts
- CEO Simon Rufer announced a $6 million seed round on November 19, 2026. J2 Ventures separately confirms its lead role.
- A 2025 SEC Form D reported $500,000 sold toward a $6 million offering. That historical disclosure is not added to the announced seed amount.
Funding history (newest first)
Seed announced; instrument composition undisclosed
2026-11-19 USD 6 million; instrument composition undisclosedSource: Read source · linkedin.com
Investors in our directory
Funds linked from CoFlo Medical's profile — open a fund page for stage focus and related deal articles.
Notable stories
- CEO funding announcement, November 19, 2026: linkedin.com (external source)
- Lead investor's own announcement, November 19, 2026: linkedin.com (external source)
- Company and product information: coflo-medical.com (external source)
- Technical description and formulation compatibility: coflo-medical.com (external source)
- Historical SEC Form D, signed November 26, 2025: sec.gov (external source)
- Founder identities and MIT entrepreneurship award, May 14, 2025: news.mit.edu (external source)
- The relationship between the 2025 offering and the 2026 announcement is not fully disclosed. No separate legal closing date, valuation, complete syndicate or current instrument mix is established. The 2025 filing's incorporation year is not treated as a verified operating launch date.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.